Fiamma Berner

发表

Defects in ER–endosome contacts impact lysosome function in hereditary spastic paraplegia

J. Lippincott-Schwartz, J. Winkler, B. Winner, 2017, The Journal of cell biology.

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

R. Dummer, L. Risch, D. Speiser, 2019, Journal of Immunotherapy for Cancer.

Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment

S. Güsewell, C. Ackermann, L. Flatz, 2018, Cancer management and research.

Cancer immunoediting by melanocyte differentiation antigen-specific T cells determines response to immune checkpoint inhibition

R. Dummer, D. Dietrich, C. Garbe, 2021 .

Pre-existing and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients

H. Rammensee, S. Held, P. Brossart, 2021 .

Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer

H. Rammensee, S. Held, P. Brossart, 2021 .

BP180-specific IgG is associated with skin adverse events, therapy response and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors.

D. Zillikens, W. Jochum, D. Bomze, 2020, Journal of the American Academy of Dermatology.

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

R. Dummer, L. Risch, M. Risch, 2019, Journal of immunotherapy.

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

D. Speiser, B. Ludewig, J. Neefjes, 2019, JAMA oncology.

Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients

T. Hundsberger, Joachim Müller, A. Moulin, 2020, Cancer Immunology, Immunotherapy.

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.

David Bomze, Tobias L. Lenz, D. Bomze, 2019, European journal of cancer.

Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival

D. Speiser, B. Ludewig, P. Baumgaertner, 2021, Oncoimmunology.

Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.

D. Schadendorf, S. Ugurel, B. Becher, 2023, Med.

Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients

L. Risch, D. Semela, M. Risch, 2021, Journal of Cancer Research and Clinical Oncology.

Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade

M. Joerger, V. Walter, N. Klümper, 2022, Science Immunology.

A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer

K. Mertz, Z. Trajanoski, Dietmar Rieder, 2019, Clinical Cancer Research.

C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer

A. Heine, P. Brossart, M. Joerger, 2022, Journal for ImmunoTherapy of Cancer.

Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer

H. Rammensee, S. Held, P. Brossart, 2021 .

Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients.

H. Rammensee, S. Held, P. Brossart, 2021, Cancer discovery.

Autoimmunity in immune checkpoint inhibitor‐induced immune‐related adverse events: A focus on autoimmune skin toxicity and pneumonitis

L. Flatz, Fiamma Berner, 2023, Immunological reviews.

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.

D. Bomze, T. Lenz, L. Flatz, 2019, European journal of cancer.

Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply.

D. Bomze, L. Flatz, Fiamma Berner, 2019, JAMA oncology.